



# KOVAI MEDICAL CENTER AND HOSPITAL LIMITED

NABH Accredited Hospital

Excellence in Healthcare

99, Avanashi Road, Coimbatore - 641 014. INDIA | Phone : (0422) 4323800, 4324000, 6803000  
Web : www.kmchhospitals.com | CIN No : L85110TZ1985PLC001659



Ref: KMCH/SEC/SE/2025-26/2498

07.11.2025

To  
Corporate Relationship Department  
BSE Limited 1<sup>st</sup> Floor,  
New Trading Ring Rotunda Building,  
P.J. Towers Dalal Street, Fort  
Mumbai - 400 001

Dear Sirs,

**Sub: Outcome of the Board Meeting.**

This is to inform you that the Board of directors at their meeting held on 07<sup>th</sup> November 2025, had inter alia considered and approved the following:

1. Un-Audited Standalone Financial Results of the Company for the Quarter / Half year ended 30<sup>th</sup> September, 2025.
2. Limited Review Report on the Financial Results of the Company for the Quarter / Half year ended 30<sup>th</sup> September, 2025.

The Board meeting commenced at 4.30 pm and concluded at 5.58 pm.

You are requested to kindly take note of the same.

Yours truly,

For Kovai Medical Center and Hospital Limited

R.Ponmanikandan  
Company Secretary





KOVAI MEDICAL CENTER AND HOSPITAL LIMITED  
Corporate Identification Number (CIN) : L85110TZ1985PLC001659

Registered Office : 99, Avanashi Road, Coimbatore - 641 014

Phone: (0422) 4323800,3083800, Fax : (0422) - 2627782

E-mail: secretarialdept@kmchhospitals.com, Website : www.kmchhospitals.com

Statement of Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2025

(₹ in lakhs)

S. No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		(Unaudited)			(Unaudited)		(Audited)
1	<b>Income</b>						
	a) Revenue from Operations	39,073.87	37,359.37	34,365.28	76,433.24	65,840.53	1,36,973.73
	b) Other Operating Income	125.58	33.40	34.30	158.98	69.58	137.57
	c) Other Income	640.84	567.62	452.64	1,208.46	966.33	2,210.42
	<b>Total Income</b>	<b>39,840.29</b>	<b>37,960.39</b>	<b>34,852.22</b>	<b>77,800.68</b>	<b>66,876.44</b>	<b>1,39,321.72</b>
2	<b>Expenses</b>						
	a) Cost of Medicines & Hospital consumables consumed	10,671.70	9,671.54	9,468.41	20,343.24	17,999.88	36,842.11
	b) Employee benefits expense	7,591.64	7,115.30	6,220.16	14,706.94	12,026.15	25,118.15
	c) Finance Costs	873.84	917.30	824.15	1,791.14	1,486.79	3,267.67
	d) Consulting Charges to Doctors	5,477.98	5,435.43	4,812.45	10,913.41	9,472.58	19,136.55
	e) Depreciation and amortization expenses	2,678.16	2,593.06	2,439.09	5,271.22	4,845.17	9,758.66
	f) Other Expenses	4,757.77	4,589.51	4,348.01	9,347.28	8,235.02	17,443.22
	<b>Total Expenses</b>	<b>32,051.09</b>	<b>30,322.14</b>	<b>28,112.27</b>	<b>62,373.23</b>	<b>54,065.59</b>	<b>1,11,566.36</b>
3	<b>Profit before Tax (1-2)</b>	<b>7,789.20</b>	<b>7,638.25</b>	<b>6,739.95</b>	<b>15,427.45</b>	<b>12,810.85</b>	<b>27,755.36</b>
4	<b>Tax expense</b>						
	a) Current Tax	1,953.87	1,958.53	1,629.05	3,912.40	3,131.40	6,729.90
	b) Taxation for earlier years	(44.76)	-	10.39	(44.76)	10.39	27.80
	c) Deferred Tax	(6.05)	(42.86)	31.61	(48.91)	24.81	103.04
	<b>Total Tax Expenses</b>	<b>1,903.06</b>	<b>1,915.67</b>	<b>1,671.05</b>	<b>3,818.73</b>	<b>3,166.60</b>	<b>6,860.74</b>
5	<b>Profit for the period from continuing operations (3-4)</b>	<b>5,886.14</b>	<b>5,722.58</b>	<b>5,068.90</b>	<b>11,608.72</b>	<b>9,644.25</b>	<b>20,894.62</b>
6	<b>OTHER COMPREHENSIVE INCOME</b>						
	<b>A) Items that will not be reclassified to profit or loss</b>						
	Remeasurement of post employment benefit obligations	(145.09)	(12.64)	(82.19)	(157.73)	(63.35)	(47.50)
	Change in equity instruments measured at FVOCI	2.92	7.42	(2.63)	10.34	(1.54)	(8.52)
	Income tax relating to items that will not be reclassified to profit or loss	36.10	2.12	21.02	38.22	16.00	18.01
	<b>Total Other Comprehensive Income</b>	<b>(106.07)</b>	<b>(3.10)</b>	<b>(63.80)</b>	<b>(109.17)</b>	<b>(48.89)</b>	<b>(38.01)</b>
7	<b>Total Comprehensive Income For The Period (5+6)</b>	<b>5,780.07</b>	<b>5,719.48</b>	<b>5,005.10</b>	<b>11,499.55</b>	<b>9,595.36</b>	<b>20,856.61</b>
8	<b>Basic and diluted Earnings Per Share</b>	<b>53.79</b>	<b>52.30</b>	<b>46.32</b>	<b>106.09</b>	<b>88.14</b>	<b>190.95</b>



ND

Statement of Assets and Liabilities

(₹ in lakhs)

Particulars	30.09.2025	31.03.2025
	(Unaudited)	(Audited)
<b>ASSETS</b>		
<b>1. Non Current Assets</b>		
(a) Property, plant & equipment	1,25,499.22	1,25,485.41
(b) Right of use assets	2,319.84	2,463.66
(c) Capital work in progress	22,405.89	14,957.20
(d) Intangible assets	548.29	320.54
(e) Intangible assets under development	261.26	442.88
(f) Financial assets		
(i) Investments	44.64	34.30
(ii) Other financial assets	1,705.79	1,762.01
(g) Other non-current assets	692.57	1,474.07
<b>Total Non Current Assets</b>	<b>1,53,477.50</b>	<b>1,46,940.07</b>
<b>2. Current Assets</b>		
(a) Inventories	1,900.91	1,561.58
(b) Financial Assets		
(i) Trade receivables	3,717.29	3,083.62
(ii) Cash & cash equivalents	10,446.43	1,429.90
(iii) Bank balances other than cash & cash equivalents	20,368.57	25,962.92
(iv) Others financial assets	907.52	400.94
(c) Other current assets	887.23	612.41
<b>Total Current Assets</b>	<b>38,227.95</b>	<b>33,051.37</b>
<b>TOTAL - ASSETS</b>	<b>1,91,705.45</b>	<b>1,79,991.44</b>
<b>EQUITY AND LIABILITIES</b>		
<b>1. Equity</b>		
(a) Equity Share Capital	1,094.23	1,094.23
(b) Other Equity	1,17,927.32	1,07,522.00
<b>Total Equity</b>	<b>1,19,021.55</b>	<b>1,08,616.23</b>
<b>2. Non Current Liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	32,478.86	34,832.90
(ii) Lease liabilities	2,927.98	3,054.14
(iii) Other financial liabilities	335.07	255.68
(b) Provisions	2,885.06	2,363.50
(c) Deferred tax liabilities (net)	3,787.31	3,874.44
(d) Other non-current liabilities	8.36	8.86
<b>Total Non Current Liabilities</b>	<b>42,422.64</b>	<b>44,389.52</b>
<b>3. Current Liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	4,170.56	3,356.98
(ii) Lease liabilities	310.78	289.74
(iii) Trade payables		
a) Dues to Micro & Small Enterprises	358.55	414.64
b) Dues to Others	2,322.31	2,534.18
(iv) Other financial liabilities	14,734.11	12,550.88
(b) Other current liabilities	7,636.74	6,717.49
(c) Provisions	728.21	740.75
(d) Current tax liabilities	-	381.03
<b>Total Current Liabilities</b>	<b>30,261.26</b>	<b>26,985.69</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>1,91,705.45</b>	<b>1,79,991.44</b>



**Notes :**

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board at its meeting held on 7th of November 2025.
- 2 The Company has reported segment information as per Indian Accounting Standards 108 - "Operating Segments" (Ind AS 108).
- 3 Figures have been regrouped, wherever necessary to conform to current period presentation.



*DR. NALLA G PALANISWAMI*

DR.NALLA G PALANISWAMI  
MANAGING DIRECTOR  
DIN : 00013536

COIMBATORE  
07.11.2025

Segment wise Revenue, Results and Capital Employed

(₹ in lakhs)

Particulars	Quarter Ended 30.09.2025	Quarter Ended 30.06.2025	Quarter Ended 30.09.2024	Half Year Ended 30.09.2025	Half Year Ended 30.09.2024	Year Ended 31.03.2025
	(Unaudited)			(Unaudited)		(Audited)
<b>Segment Revenue</b>						
Healthcare	37,107.93	34,305.14	32,316.03	71,413.07	62,032.91	1,27,856.35
Education	2,091.52	3,087.63	2,083.55	5,179.15	3,877.20	9,254.95
<b>Sub-total</b>	<b>39,199.45</b>	<b>37,392.77</b>	<b>34,399.58</b>	<b>76,592.22</b>	<b>65,910.11</b>	<b>1,37,111.30</b>
Less : Inter-segment revenue	-	-	-	-	-	-
<b>Revenue from Operations</b>	<b>39,199.45</b>	<b>37,392.77</b>	<b>34,399.58</b>	<b>76,592.22</b>	<b>65,910.11</b>	<b>1,37,111.30</b>
<b>Segment Results</b>						
Profit/(loss) before interest and tax						
Healthcare	8,768.99	7,637.60	7,633.94	16,406.59	14,442.28	30,512.78
Education	535.18	1,583.39	520.84	2,118.57	990.33	3,240.93
<b>Sub-total</b>	<b>9,304.17</b>	<b>9,220.99</b>	<b>8,154.78</b>	<b>18,525.16</b>	<b>15,432.61</b>	<b>33,753.71</b>
Add: Unallocated Income	-	-	-	-	-	-
Less : Finance Cost	873.84	917.30	824.16	1,791.14	1,486.79	3,267.67
Unallocated expenses	641.13	665.44	590.67	1,306.57	1,134.97	2,730.68
<b>Profit before tax (PBT)</b>	<b>7,789.20</b>	<b>7,638.25</b>	<b>6,739.95</b>	<b>15,427.45</b>	<b>12,810.85</b>	<b>27,755.36</b>
<b>Capital employed</b>						
(Segment assets - Segment liabilities)						
<b>(a) Healthcare</b>						
Segment assets	1,60,940.89	1,49,481.22	1,27,934.11	1,60,940.89	1,27,934.11	1,43,336.99
Segment liabilities	(53,648.39)	(52,406.48)	(50,119.69)	(53,648.39)	(50,119.69)	(51,891.14)
<b>(b) Education</b>						
Segment assets	24,459.09	28,106.61	30,030.36	24,459.09	30,030.36	30,536.77
Segment liabilities	(14,163.24)	(12,151.47)	(12,276.33)	(14,163.24)	(12,276.33)	(13,402.72)
<b>(c) Unallocated</b>						
Assets	6,305.45	6,326.95	6,540.50	6,305.45	6,540.50	6,117.68
Liabilities	(4,872.25)	(5,021.12)	(4,753.96)	(4,872.25)	(4,753.96)	(6,081.35)
<b>Total</b>	<b>1,19,021.55</b>	<b>1,14,335.71</b>	<b>97,354.99</b>	<b>1,19,021.55</b>	<b>97,354.99</b>	<b>1,08,616.23</b>



*M. Nalla G. Palaniswami*  
 DR. NALLA G PALANISWAMI  
 MANAGING DIRECTOR  
 DIN : 00013536

COIMBATORE  
 07.11.2025



STATEMENT OF CASH FLOW FOR THE PERIOD ENDED 30TH SEPTEMBER 2025

(₹ in lakhs)

Particulars	30th September 2025 (Unaudited)		30th September 2024 (Unaudited)		31st March 2025 (Audited)	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES:</b>						
Profit before taxation and exceptional items		15,427.45		12,810.85		27,755.36
Adjustment for:						
Depreciation and amortisation expense	5,271.22		4,845.17		9,758.66	
Exchange fluctuation loss/(gain) - (net)	-		0.12		2.70	
Finance cost	1,787.40		1,488.76		3,263.91	
Dividend Income	(1.22)		(0.98)		(0.98)	
Non Cash transactions	11.16		1.75		(46.13)	
Loss/(profit) on Sale of Property,Plant & equipment (net)	142.60		17.48		18.60	
		7,211.16		6,352.30		12,996.76
<b>Operating cash flow before working capital changes</b>		<b>22,638.61</b>		<b>19,163.15</b>		<b>40,752.12</b>
(Increase) / Decrease in non current & current financial assets	(1,439.10)		(1,862.50)		(1,857.89)	
(Increase) / Decrease in other non current & current assets	(274.82)		(291.14)		(188.34)	
Increase / (Decrease) in non current & current financial liabilities	(609.87)		999.49		1,520.22	
(Decrease) / Increase in other non current & current liabilities	1,276.99		(511.68)		1,162.28	
		(1,046.80)		(1,665.83)		636.27
<b>Cash generated from operations</b>		<b>21,591.81</b>		<b>17,497.32</b>		<b>41,388.39</b>
Income Tax paid		(4,364.20)		(2,931.91)		(6,096.92)
<b>Net cash generated from operating activities (A)</b>		<b>17,227.61</b>		<b>14,565.41</b>		<b>35,291.47</b>
<b>B. CASH FLOW FROM/ (USED IN) INVESTING ACTIVITIES:</b>						
Purchase of Property, Plant & Equipment, CWIP & intangible assets	(9,347.39)		(18,823.57)		(35,309.94)	
Proceeds relating to Property, Plant & Equipment	81.04		83.63		92.54	
Investment/Sale in Equity Instruments	-		2.53		2.53	
Dividend Income	1.22		0.98		0.98	
<b>Net cash from / (used in) investing activities (B)</b>		<b>(9,265.13)</b>		<b>(18,736.43)</b>		<b>(35,213.89)</b>
<b>C. CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES:</b>						
Long term Borrowings (Net off Repayment)	(1,540.45)		11,079.01		10,749.79	
Short term Borrowings (Net)	-		-		-	
Repayment of lease liabilities	(295.92)		(254.90)		(538.78)	
Finance Cost paid	(1,621.53)		(1,283.44)		(2,927.36)	
Dividend Paid	(1,082.40)		(1,073.21)		(1,074.28)	
<b>Net cash from / (used in) financing activities (C)</b>		<b>(4,540.30)</b>		<b>8,467.46</b>		<b>6,209.37</b>
Net increase / (decrease) in cash and cash equivalents (A+B+C)		<b>3,422.18</b>		<b>4,296.44</b>		<b>6,286.95</b>
Cash and cash equivalents at the beginning of the period		27,392.82		21,105.87		21,105.87
Less: Bank Balances not considered as Cash & Cash equivalents as per Ind AS 7		20,368.57		16,605.75		25,962.92
Cash and Cash equivalent at the end of the period		<b>10,446.43</b>		<b>8,796.56</b>		<b>1,429.90</b>



**Independent Auditor's Review Report on Interim Financial Results**

To the Board of Directors

**Kovai Medical Center and Hospital Limited**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Kovai Medical Center and Hospital Limited** ('the Company') for the quarter and six months ended 30<sup>th</sup> September 2025 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 - "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") and in compliance with regulation 33 of the listing regulations and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Coimbatore - 641 011

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VKS Aiyer & Co  
Chartered Accountants  
ICAI Firm Registration No.000066S



*[Handwritten signature]*

**C S Sathyanakayanan**  
Partner  
Membership No.028328  
UDIN: 25028328BMIZS6156

Place: Coimbatore  
Date: 07-11-2025